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Abstract 
Capillary electrophoresis has drawn considerable attention in the 
past few years, particularly in the field of chiral separations 
because of its high separation efficiency. However, its routine use 
in therapeutic drug monitoring is hampered by its low sensitivity 
due to a short optical path. W e have developed a capillary zone 
electrophoresis (CZE) method using 2mM of hydroxypropyl-Β-
cyclodextrin as a chiral selector, which allows base-to-base 
separation of the enantiomers of mianserin (MIA), 
desmethylmianserin (DMIA), and 8-hydroxymianserin (OHMIA) . 
Through the use of an on-column sample concentration step after 
liquid-liquid extraction from plasma and through the presence of 
an internal standard, the quantitation limits were found to be 5 
ng/mL for each enantiomer of MIA and DMIA and 15 ng/mL for 
each enantiomer of OHMIA. To our knowledge, this is the first 
published CE method that allows its use for therapeutic monitoring 
of antidepressants due to its sensitivity down to the low nanogram 
range. The variability of the assays, as assessed by the coefficients 
of variation (CV) measured at two concentrations for each 
substance, ranged from 2 to 14% for the intraday (eight replicates) 
and from 5 to 14% for the interday (eight replicates) experiments. 
The deviations from the theoretical concentrations, which 
represent the accuracy of the method, were all within 12.5%. A 
linear response was obtained for all compounds within the range 
of concentrations used for the calibration curves (10-150 ng/mL 
for each enantiomer of MIA and DMIA and 20-300 ng/mL for 
each enantiomer of OHMIA) . Good correlations were calculated 
between [(R) + (5)]-MIA and DMIA concentrations measured in 
plasma samples of 20 patients by a nonchiral gas chromatography 
method and CZE, and between the (R)- and (S)-concentrations of 
MIA and DMIA measured in plasma samples of 37 patients by a 
previously described chiral high-performance liquid 
chromatography method and CZE. Finally, no interference was 
noted from more than 20 other psychotropic drugs. Thus, this 
method, which is both sensitive and selective, can be routinely 
used for therapeutic monitoring of the enantiomers of MIA and its 
metabolites. It could be very useful due to the demonstrated 
interindividual variability of the stereoselective metabolism of 
MIA. 
* Author to whom correspondence should be addressed. 
Introduction 
Mianserin (MIA) is a tetracyclic antidepressant drug with 
less anticholinergic activity and cardiotoxicity than the tri­
cyclic antidepressants (1). MIAs main metabolites are 8-hy­
droxymianserin (OHMIA), desmethylmianserin (DMIA), and 
mianserin-Af-oxide (OXMIA) (see Figure 1). The latter is phar­
macologically inactive, whereas OHMIA and DMIA probably 
contribute to the pharmacological activity of the parent drug 
(2). MIA is administered as a racemate, and (S)-MIA is consid­
ered the more potent antidepressant enantiomer (2). 
In a previous study, we described a high-performance liquid 
chromatographic (HPLC) method with a cyclodextrin chiral 
column (Cyclobond IRSP) which allows the measurement of 
the enantiomers of MIA, DMIA, and OHMIA. This method was 
used for the analysis of plasma and urine of 10 MIA-treated 
patients (3). We demonstrated an enantioselectivity in the 
metabolism of MIA and a large interindividual variability in the 
S-R ratios of MIA and its metabolites, which could partially 
explain why, until now, no consistent relationship has been 
established between the therapeutic response and total ([R] + 
[S]) plasma levels of this antidepressant to our knowledge (3). 
However, with the above-mentioned method, it was not pos­
sible to obtain a base-to-base separation for MIA and DMIA. 
Furthermore, a nonlinear response was observed for OHMIA 
within the range of concentrations used for the calibration 
curves, which was probably due to the nature of the detection 
system used (fluorescence after photochemical reaction) and 
made the reliable quantitation of this metabolite difficult. 
Capillary electrophoresis (CE) is a method that has drawn 
considerable attention in the past few years, particularly in the 
field of chiral separations because of its high separation 
efficiency, its easy use, and its low cost (minimal use of reagents 
and cheap columns compared to expensive and usually short­
lived chiral gas chromatography [GC] or HPLC columns). We 
have developed a capillary zone electrophoresis (CZE) method 
for the separations of MIA, DMIA, and OHMIA using hydroxy-
propyl-P-cyclodextrin (HPC) with resolution factors greater 
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than 1 and a linear response within the range of concentrations 
used for the calibration curves. Because plasma concentrations 
of MIA and its metabolites in MIA-treated patients are in the low 
nanogram per milliliter range, and given the poor sensitivity of 
the CE apparatus (due to a short optical path), an on-column 
sample preconcentration (4) after a liquid-liquid extraction 
from the plasma samples was necessary. 
sample concentration were performed as follows: (a) pressure 
injection (50 rnbar) of Milli-Q water for 3.7 s, (b) voltage 
injection (5 kV) of the sample for 10 s, and (c) pressure injec­
tion (50 mbar) of the running buffer for 3.7 s. The vials con­
taining the anode and cathode buffer were emptied and refilled 
with running buffer before each analysis. The detector was set 
at 211 nm with a band width of 20 nm. 
Experimental 
Reagents 
MIA-HC1, desmethylmianserin-HCl, 8-hydroxymianserin 
maleate, (+)-(5)-mianserin maleate, and (-)-(R)-mianserin 
maleate were kindly provided by Organon (Oss, The Nether­
lands). Propyl-norclozapine (PNC, internal standard) was syn­
thesized as previously described (5). Hydroxypropyl-β-cy-
clodextrin (degree of substitution, 6-9; molecular weight 
calculated with seven substitutions, 1541.5) was from Aldrich 
(Fluka, Buchs, Switzerland). 
The stock solution of buffer consisted of a 0.075M phos­
phoric acid aqueous solution adjusted to pH 3.0 with concen­
trated triethylamine. Unless otherwise stated, it contained 2mM 
of hydroxypropyl-β-cyclodextrin. Before use, it was filtered 
through a 0.22-pm pore size filter and degassed in an ultrasonic 
bath. Stock solutions of racemic MIA and DMIA and racemic 
OHMIA and PNC were made at 1 mg/mL in 0.1N HC1 and in 
methanol, respectively. Working solutions were made at 1 or 
10 ng/μL 0.1N HC1. All solutions were stored at -20°C until 
used. Water was obtained from a Milli Q-RG apparatus (Milli-
pore, Le Mont-sur-Lausanne, Switzerland), and all other 
reagents were of analytical or HPLC grade. Injection vials were 
silanized before each use (with 4% dimethyl-dichlorosilane in 
toluene). 
Instrumentation and CE conditions 
An HP CE system with a diode-array detector (Hewlett-
Packard, Geneva, Switzerland) was used with an untreated HP 
silica capillary column (total length, 64.5 cm; effective length, 
56 cm; 50-μm i.d.; bubble factor, 3). Standard operating con­
ditions, unless stated otherwise, were as follows: the voltage 
was 30 kV, and the temperature was 20°C. At the beginning of 
each run, the capillary was flushed with 0.1N NaOH for 2 min 
and with a running buffer for 3 min. Injection and on-column 
where tx is the migration time of the enantiomer (in minutes) 
and (W h / 2 ) x is the peak width of the enantiomer at half its 
height (in minutes). 
Extraction of plasma samples 
For the determination of free MIA and DMIA, 300 ng of the 
internal standard, 0.5 mL 1M carbonate buffer (pH 9.4), and 
6 mL n-heptane-ethyl acetate (80:20, v/v) were added to a 
1-mL aliquot of heparinized plasma. The extraction was then 
performed on a shaker for 20 min. After centrifugation (6 min, 
3400 g, 8°C), the organic layer was transferred to another tube 
containing 1.2 mL 0.1N Hcl. After 15 min of shaking and 6 min 
of centrifugation, the organic phase was discarded, and the 
aqueous phase was transferred to another tube containing 
150 μL toluene-isoamyl alcohol (85:15, v/v) and 1 mL 1M car­
bonate buffer (pH 9.4). After 20 min of shaking and 6 min of 
centrifugation, the organic phase was transferred to a home­
made microtube (length, 40 mm; internal diameter, 3 mm) 
which allowed a good visualization of the two phases. The 
organic phase was then pipetted with care to avoid contami­
nation by the aqueous phase and was gently transferred to the 
injection vial above a layer containing 100 μL of 0.0001% 
diethylamine (DEA). The organic phase was then gently dried 
under N 2 at 40°C until the final volume was approximately 
50 μL water containing DEA. The vial was then left uncapped 
at 40°C without N 2 for 30 min to allow any remaining toluene 
to evaporate. The vial was then thoroughly vortexed for 15 s, 
and the aquous contents were injected into the CE. 
For the determination of total (free + conjugated) MIA, 
DMIA, and OHMIA, 1 mL of plasma was incubated with 1 mL 
of 0.2M acetate buffer (pH 5.0), 50 μL 4% sodium azide, 300 ng 
of the internal standard, and 200 μL of a 
solution of H. pomatia (β-glucuronidase 
(25,000 units/mL of 0.2% NaCl) (Sigma, St. 
Louis, MO) at 37°C overnight. The mixture 
was then treated as previously described. 
Calibration curve, sensitivity, and 
reproducibility 
For calculation, corrected areas were 
used (area divided by migration times). 
Calibration curves were prepared by adding 
known amounts of (S)- and (R)-enan-
t iomers of MIA and its metabol i tes 
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Figure 1. Chemical structures of MIA and its principal human metabolites. 
Resolution 
The resolution was calculated with the following expression 
(6): 
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(10-150 ng/mL for each enantiomer of MIA and DMIA and 
20-300 ng/mL for each enantiomer of OHMIA) and PNC (300 
ng/mL) to a 1-mL drug-free plasma. Within-day and interday 
replicates were calculated with plasma containing 20 or 100 
ng/mL of each enantiomer of MIA and DMIA and 50 or 200 
ng/mL of each enantiomer of OHMIA. For each enantiomer of 
each compound, quantitation limits were set at the minimal 
plasma concentration, which produced, after extraction and in­
jection, a signal-to-noise ratio of at least four, a coefficient of 
variation (CV) for replicate determination (nine replicates) of 
20% or less, and a deviation of the mean value less than 20% 
of the actual value. 
Identification of the enantiomers of MIA and its metabolites 
on the chromatogram 
Pure enantiomers were only available for MIA ([S]-MIA and 
[R]-MIA). The order of elution of the (S)- and (R)-forms of 
DMIA and OHMIA was determined by analyzing a patient's 
plasma sample that had been previously analyzed by HPLC (3). 
Results and Discussion 
Optimization of the achiral and chiral separation parameters 
The achiral separation of MIA from DMIA and OHMIA was 
first tested with three buffers (H3PO4-KH2PO4, H 3PO 4-triethyl-
amine [TEA], and H 3PO 4-triethanolamine [TENA]) at two con­
centrations (100 and 50mM) and at pH 3.0 without cyclodex-
trin (6). A complete separation of the three substances was 
obtained with the three buffers at the two concentrations, but 
the best resolution was obtained with TEA (TEA > TENA > 
KH2PO4) and at lOOmM (data not shown). A shorter migration 
time was obtained with 50mM buffers and with TENA (TENA < 
KH 2PO 4 < TEA). Finally, the best peak shapes (symmetric 
peaks) were obtained with TEA (data not shown). An H 3 PO 4 -
TEA 75mM buffer was chosen for subsequent experiments. 
HPC is probably the most used cyclodextrin for chiral sep­
aration in CZE. It was the first that we tested, and because 
an excellent separation was obtained, no attempt to try other 
cyclodextrins was made. Figure 2 shows a plot of resolutions 
between each pair of enantiomers of MIA, DMIA, and OHMIA 
as a function of HPC concentrations. Excellent separa­
tions were obtained over a wide range of HPC concentrations 
Figure 2. Effect of hydroxypropyl-β-cyclodextrin concentrations on 
resolution of racemic MIA (•), DMIA (•) , and OHMIA (•) . 
(1.25-45mM); the maximum was about 15mM. However, 
between 5 and 45mM HPC, it was not possible to separate the 
six isomers due to comigration of the enantiomer of one sub­
stance with the enantiomer of another substance. The com­
plete separation of the six isomers was only possible around 
2.5mM, a separation which was again lost at 1.25mM. Some 
additional control experiments allowed us to determine that 
the best separation was obtained at a concentration of 2mM 
HPC diluted in H3PO4-TEA. Finally, using different pH values 
between 2.0 and 5.0 and different temperatures (15, 20, and 
30°C), it was found that the best separation, without excessive 
increase in migration time, was obtained at pH 3.0 and 20°C. 
Figure 3 shows the electrophoretic separation of the enan­
tiomers of MIA and its metabolites after extraction of a blank 
plasma sample spiked with various amounts of substances (see 
figure caption) and injection into the CE apparatus. It is worth 
noting that, with the highest concentrations of the calibration 
curve, distorted peak shapes were produced due to overloading, 
but the calibration curve was still linear within that range. 
Validation of enantiomer determination in plasma 
It is well-known that a weak point of CE is its poor sensitivity 
due to a short optical path. A sensitive method down to a low 
nanogram concentration is needed, so a field-amplified sample 
injection for positive ion injection method (4) was attempted 
and found to give excellent results: an approximately 50-100-
fold concentration of the sample was obtained. In summary, the 
method is based on the following sequence and principles. 
First, a small plug of diluted buffer (in our case, deionized 
water) was introduced into the column before sample injection. 
This resulted in an electric field at the injection point that 
was much stronger than that in the column. The analytes pre­
pared in the diluted buffer were then electrically injected into 
the column and concentrated at the beginning of the column 
buffer. Because stacking and broadening work against each 
other, there is an optimal length of water plug that can be in­
troduced into the column that still achieves high resolution 
(4). Several lengths of water plug (pressure injection of 50 
mbar from 1.8 to 7.4 s) and several times (5-40 s) or voltage 
(5-10 kV) for the electroinjection were tested. The sequence of 
injection as described in the Experimental section was found to 
be optimal. 
When developing the method, a large variability in the mea­
sured concentrations of MIA and its metabolites, OHMIA in 
particular, was found. At this time, the organic phase was com­
pletely dried in the last step of the extraction method, and the 
dry residue was reconstituted in water before injection. An 
adsorption of the hydroxy-metabolites to the walls of the injec­
tion vials was thus suspected. The procedure (described in the 
Experimental section) consisted of transferring the organic 
phase to the injection vial on the top of a layer of 100 μL 
0.0001% DEA and drying the mixture until the final volume 
was approximately 50 μL DEA-containing water; this was found 
to solve the problem. However, it is worth noting that, al­
though toluene is very volatile, its presence, even in trace 
amounts, resulted in small peaks of MIA, as measured by CE 
(data not shown). An additional 30-min drying step at 40°C 
without N 2 was added to ensure a complete evaporation of 
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toluene. We also decided to silanize all injection vials and use 
very dilute concentrations of DEA in the last step to further 
minimize adsorption (a control experiment showed that this 
very dilute concentration of DEA did not decrease the efficacy 
of the on-column sample preconcentration). 
It must be emphasized that in order to decrease adsorption 
and avoid toluene in the final phase, all steps, as described 
above, were essential for the reproducibility of the method. 
Another important point is that no carbonate buffer, even as a 
small contamination, was transferred with the organic phase 
into the injection vial at the last extraction step (for this, we 
used a homemade microtube to allow a clear visualization of 
the two phases; see Experimental section). Otherwise, this 
Figure 3. Electropherogram of (A) a blank plasma, (B) a blank plasma spiked with 100 ng/mL of each 
enantiomer of MIA and DMIA and with 200 ng/mL of each enantiomer of OHMIA, and (C) a nonhy-
drolyzed and (D) hydrolyzed plasma from a patient treated with 30 mg of racemic MIA for 50 days. 
Typical retention times were 20.3, 20.9, 21.5, 22.5, 23.7, 26.8, and 15.4 min for (S)-DMIA (peak 1), 
(S)-MIA (peak 2), (R)-DMIA (peak 3), (R)-MIA (peak 4), (S)-OHMIA (peak 5), (R)-OHMIA (peak 6), and 
propylnorclozapine (internal standard, peak 7). 
wbuld raise the ionic concentration of the sample and prevent 
the stacking process from occurring, resulting in very small or 
undetectable peaks, including that of the internal standard. 
However, in such cases, it was possible to re-extract (last extrac­
tion step) and reinject the sample. MIA and its metabolites 
were stable in the dilute solution of DEA for at least four days 
at room temperature and for at least two months in plasma at 
-20°C (data not shown). Finally, it should be mentioned that the 
on-column sample concentration of the injection step affected, 
to a minor extent, the total content of the drug in the injection 
vial, which allowed several injections from the same vial. 
Table I shows a summary of the statistical data from the 
analysis of the MIA, DMIA, and OHMIA enantiomers. To sum­
marize, the mean correlation coefficients 
for the calibration curves (five concentra­
tions, from 10 to 150 ng/mL for MIA and 
DMIA and from 20 to 300 ng/mL for 
OHMIA) obtained from four separate 
experiments ranged from 0.992 to 0.999. 
Recovery was found to be satisfactory for all 
compounds, ranging from 72 to 90%. How­
ever, it is worth noting that very large coef­
ficients of variation were calculated (up to 
58%), which was probably due to the vari­
able efficacy of the injection method rather 
than that of the extraction method. This 
variability was not detrimental to the 
method, given the presence of an internal 
standard. Indeed, the variability of the 
assays, as assessed by the CVs measured at 
two concentrations for each substance, was 
always less than 14% for both the intraday 
(eight replicates) and interday (eight repli­
cates) experiments. The deviations from the 
theoretical concentrations, which represent 
the accuracy of the method, were all within 
12.5%. The quantitation limits were found 
to be 5 ng/mL for each enantiomer of MIA 
and DMIA and 15 ng/mL for each enantio­
mer of OHMIA. 
Migration t ime reproducibi l ty was 
acceptable; the CVs of 10 successive injec­
tions of the same sample were less than 
1.5%. Furthermore, the CVs calculated for 
the relative migration times of one enan­
tiomer compared with the internal stan­
dard or calculated for the (S)-enantiomer 
compared with the (R)-enantiomer did not 
exceed 1.35 and 0.2%, respectively. The 
specificity of the assay was also controlled; 
500 ng of each of the following substances 
were dried, reconstituted in 100 μL of 
0.0001% DEA, and injected into the CE 
with the on-column sample concentra­
tion method: amitriptyline, nortriptyline, 
citalopram, norcitalopram, clozapine, nor­
clozapine, clomipramine, norclomipramine, 
fluvoxamine, fluoxetine, norfluoxetine, 
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imipramine, desipramine, paroxetine, maprotiline, methadone, 
sertraline, norsertraline, thioridazine, trimipramine, and nor-
trimipramine. No peaks were detected for up to 30 min, except 
for clozapine, norclozapine, and thioridazine, which migrated 
before PNC, the internal standard (relative migration com­
pared to PNC: 0.87,0.76, and 0.61, respectively). It should be 
mentioned that clozapine and norclozapine could also probably 
be used as internal standards. However, PNC, which was syn­
thesized in our laboratory for the analysis of clozapine, had the 
advantage that it could not be found in any patients. 
Figures 3C and 3D show the electrophoretic separations of 
MIA and its metabolites after liquid-liquid extraction of non-
hydrolyzed and hydrolyzed plasma from a patient treated with 
30 mg of racemic MIA per day for 50 days. The measured con­
centrations of (S)-MIA, (R)-MIA, (S)-DMIA, and (R)-DMIA in 
nonhydrolyzed plasma (free drug concentrations) were 41,22, 
7, and 22 ng/mL, respectively. The measured concentrations 
of (S)-MIA, (R)-MIA, (S)-DMIA, (R)-DMIA, (S)-OHMIA, and 
(R)-OHMIA in hydrolyzed plasma (total drug concentrations) 
were 64, 80,16,31,123, and 47, respectively. This confirmed 
the stereoselectivity in the metabolism of MIA as previously 
described (3). A set of 20 plasma samples from MIA-treated 
patients, which were sent to our laboratory for therapeutic 
drug monitoring of MIA and DMIA (nonstereospecific GC 
assay) (7), were reanalyzed by CE. Figure 4 shows the good cor­
relations between the concentrations of MIA obtained with 
the two methods (the [R]- and [5]-concentrations obtained by 
CE were added before comparison with the concentrations 
obtained by GC). Similar results were obtained for DMIA 
(correlation coefficient = 0.98, 20 samples, slope = 0.861, 
intercept =12.1). Finally, for a clinical study, plasma was col­
lected from 37 patients receiving various doses of racemic 
MIA for at least one week (C.B. Eap, C.A. de Mendonca Lima, 
F. Macciardi, B. Woggon et al., submitted to Therapeutic Drug 
Monitoring, 1997), and free concentrations of MIA and DMIA 
(nonhydrolyzed plasma samples) were measured by CZE and 
HPLC (3). Figure 5 shows the good correlations between the 
concentrations of (S)-MIA obtained with the two methods. 
Table 1. Statistical Data from the Analysis 
(S)-MIA 
of MIA, DMIA, 
(R)-MIA 
and OHMIA Ena 
(S)-DMIA 
ntiomers 
(R)-DMIA (S)-OHMIA (R)-OHMIA 
Calibration (four replicates) 
Range (ng/mL) 10-150 10-150 10-150 10-150 20-300 20-300 
Slope: mean ± SD (CV) 1.88 ±0.08 (4) 1.81 ±0.04(2) 2.12 ±0.06 (3) 1.82 ±0.11 (6) 1.82 ±0.16 (9) 1.70 ±0.13 (8) 
Intercept: mean (range) -0.0053 (-0.0169, -0.009 (-0.0105, -0.019 (-0.0289, -0.0178 (-0.0265, -0.0916 (-0.163, -0.0851 (-0.155, 
0.0048) -0.0071) -0.0103) -0.0095) -0.046) -0.05) 
Correlation coefficient: 0.998 (0.997- 0.996 (0.993- 0.998 (0.998- 0.996 (0.994- 0.996 (0.992- 0.997 (0.996-
mean (range) 0.999) 0.998) 0.999) 0.997) 0.998) 0.998) 
Retention times 
CV for 10 replicate injections 1.29 1.33 1.31 1.33 1.35 1.48 
Recovery (10 replicates) 
Concentration used (ng/mL) 20 20 20 20 50 50 
Recovery (%): mean ± SD (CV) 86 ± 48 (55) 90 ±49 (54) 80 ±45 (56) 72 ± 42 (58) 87 ± 46 (52) 84 ±45 (53) 
Within-day variation (eight replicates) 
Theoretical values (ng/mL) 20 20 20 20 50 50 
Measured values (ng/mL): 
mean ± SD (CV) 19.6 ±0.3 (2) 21.7 ±0.6 (3) 20.2 ± 0.9 (5) 22.5 ±1.1 (5) 52.6 ±5.2 (10) 51.2 ±5.6 (11) 
Percentage of theory 98 108.5 101 112.5 105.2 102.4 
Theoretical values (ng/mL) 100 100 100 100 200 200 
Measured values (ng/mL): 
mean ± SD (CV) 99.9 ± 5.8 (6) 100.3 ±5.6 (6) 98.2 ±10.9 (11) 98.9 ±10.2 (10) 191.3 ±26.4 (14) 191.8 ±25.7 (13) 
Percentage of theory 99.9 100.3 98.2 98.9 95.7 95.9 
Day-to-day variation (eight replicates) 
Theoretical values (ng/mL) 20 20 20 20 50 50 
Measured values (ng/mL): 
mean ± SD (CV) 20.7 ±1.6 (8) 20.1 ±1.7 (9) 19.6 ±1.7 (9) 19.7 ±1.9 (10) 45.6 ± 3.7 (8) 46.0 ±3.6 (8) 
Percentage of theory 103.5 100.5 98 98.5 91.2 92 
Theoretical values (ng/mL) 100 100 100 100 200 200 
Measured values (ng/mL): 
mean ± SD (CV) 95.5 ±12.2 (13) 94.2 ±12.8 (14) 98.4 ± 8.0 (8) 95.4 ± 7.3 (8) 206.5 ±10.5 (5) 208.3 ±11.6 (6) 
Percentage of theory 95.5 94.2 98.4 95.4 103.3 104.2 
Quantitation limit (nine replicates) 
Theoretical values (ng/mL) 5 5 5 5 15 15 
Measured values (ng/mL): 
mean ± SD (CV) 5.1 ±0.5 (10) 4.9 ±0.7 (15) 4.8 ±0.7 (15) 5.2 ± 0.4 (8) 16.3 ±3.2 (19.7) 16.3 ±3.1 (19) 
Percentage of theory 102 98 96 104 108.7 108.7 
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Similar results were obtained for (R)-MIA, (S)-DMIA, and (R)-
DMIA (correlation coefficient = 0.91,35 samples, slope = 0.893, 
intercept = 2; correlation coefficient = 0.93,14 samples, slope 
= 0.683, intercept = 4.3; and correlation coefficient = 0.95,33 
samples, slope = 0.738, intercept = 5.7, respectively [an unequal 
number of values for each isomer were included because certain 
concentrations were below the quantitation limits]). 
Conclusion 
To summarize, this CZE method is a good alternative to a 
previously described HPLC method (3). Indeed, from a general 
point of view, CE has well-known advantages over HPLC, such 
as its simplicity of use, the low cost of reagents, and the low 
cost of columns (particularly important when considering 
chiral columns that are expensive and often short-lived). Fur­
thermore, the high separation efficiency of CE with the present 
Figure 4. Spearman correlations between ([R] + [S])-MIA concentrations 
as measured by GC and CE. y - 7A + 0.969x, 20 replicates, correlation 
coefficient = 0.95. 
Figure 5. Spearman correlation between (S)-MIA concentrations 
measured by HPLC and CE. y= 5.3 + 0.837x, 36 replicates, correlation 
coefficient = 0.97. 
method allows a base-to-base separation for all enantiomers. 
Until now, the inherent lack of sensitivity of CE prevented its 
use when a sensitivity down to the low nanogram level was 
needed. Using an on-column sample preconcentration step 
with the presence of an internal standard resulted in a quanti­
tation limit that allows the use of this method for therapeutic 
monitoring of antidepressants. To our knowledge, this is the 
first time that this has been demonstrated. Using the same de­
velopment scheme, a method has now been introduced in our 
laboratory for the determination of the enantiomers of trim­
ipramine and metabolites (Eap et al., manuscript in prepara­
tion). Finally, we believe that CE with an on-column sample 
preconcentration step could also be useful for the determina­
tion of nonchiral antidepressants or other drugs. 
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